Todd Zavodnick, Dermavant CEO
May 16, 2023 07:00 AM EDT
R&D

Der­ma­van­t's Vta­ma works again in eczema as Roivant sub­sidiary seeks la­bel ex­pan­sion next year

Kyle LaHucik

Senior Reporter

Al­most a year to the day af­ter Der­ma­vant Sci­ences land­ed its first FDA ap­proval for plaque pso­ri­a­sis for Vta­ma, the drug­mak­er is out with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

As the XBI suf­fers, Q1 shows a few com­fort­ing signs of un­der­ly­ing sta­bil­i­ty

Up­dat­ed: Roche’s $50B US in­vest­ment in­cludes pre­vi­ous build an­nounce­ments

Gala­pa­gos CEO Paul Stof­fels to step down, for­mer Neumo­ra chief to lead spin­out

Drug­mak­ers stock­pile in­ven­to­ry in the US, seek­ing to get ahead of Trump tar­iffs

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times